STOCKS TELEGRAPH

Tag: BEAT stock

  • How HeartBeam (BEAT) Stock Continued The Rally After-Hours?

    How HeartBeam (BEAT) Stock Continued The Rally After-Hours?

    HeartBeam, Inc. (NASDAQ: BEAT) witnessed a sustained upswing in its stock during the after-market trading on Wednesday, extending the positive momentum observed in the regular trading session. The stock exhibited a noteworthy 6.17% increase, reaching $2.41 in the extended session, building upon its earlier gain of 4.13% during regular trading, concluding at $2.27. Despite the absence of any overtly impactful news prompting this surge in BEAT stock, attention can be redirected to recent corporate advancements for a more profound understanding.

    HeartBeam (BEAT) has recently disclosed substantial progress in the integration of artificial intelligence (AI) into its exclusive vectorelectrocardiography (VECG) technology. Noteworthy aspects of these advancements involve the introduction of new leadership and advisory roles within the company. By synergizing machine learning methodologies with the proprietary VECG technology, HeartBeam aspires to furnish medical practitioners with unparalleled diagnostic and prognostic insights pertaining to cardiac health.

    The company contends that such insights will surpass the information attainable through a conventional 12-lead electrocardiogram (ECG). The fundamental VECG technology employed by BEAT captures three-dimensional signals emanating from the heart, subsequently transforming them into a comprehensible 12-lead ECG. Tailored for use with portable, patient-friendly devices, the inaugural application of this platform technology is manifest in the HeartBeam AIMIGo—a credit card-sized device, unparalleled in its ability to provide a 12-lead ECG, thereby facilitating the remote assessment of cardiac symptoms.

    Distinguishing itself from the conventional 12-lead ECG, the HeartBeam technology amasses a more extensive dataset by capturing signals in three projections (X, Y, Z), collectively generating a comprehensive 3D mapping of the heart’s electrical activity. Employing AI to scrutinize these data-rich signals, HeartBeam anticipates an enhancement in diagnostic precision, capable of revealing nuanced details that elude current 12-lead ECGs.

    This includes intricate heart rhythms, subtle indicators of deteriorating cardiac health, and previously undetected cardiac events. Furthermore, the device, when used consistently by the same patient over time, generates a series of readings per patient, constituting valuable diagnostic information. HeartBeam envisions this as a distinctive opportunity to construct a thorough repository of data, potentially unlocking personalized AI-driven insights to advance cardiac care.

  • HeartBeam, Inc. (BEAT) stock has climbed to 12.20% – Learn why is this happening?

    HeartBeam, Inc. (BEAT) has seen a push of 12.20% in aftermarket following the announcement of a partnership with LIVMOR. However, the last trading session closed at $2.05 with a decrease of 5.96%.

    Partnership of BEAT with LIVMOR – What’s up?

    BEAT announced on 2nd February 2022 that it has entered into a partnership with LIVMOR. It is a digital health solutions firm that has partnered with BETA in order to create a HeartBeam-branded version of LIVMOR’s Halo+ FDA-cleared turnkey system for remote patient monitoring that connects doctors and patients. Moreover, the company will be able to reach the FDA submission deadline for the initial product. The product is an easy-to-use heart attack detection software solution for Emergency Department settings.

    Furthermore, LIVMOR has successfully built a patient-engaged remote monitoring system of crucial physiological indicators, which BEAT believes may be converted to work with the Emergency Department software solution to improve MI detection accuracy. In addition, LIVMOR’s regulatory experience is a valuable asset to the company as the team pursues FDA authorization for the HeartBeam Platform. Lastly, the team is excited to collaborate with the LIVMOR on getting the software ready for FDA submission later this year.

    Establishment of Scientific Advisory Board & Appointment of Michael Gibson

    On 27th January 2022, BEAT reported that the company has established a  Scientific Advisory Board and also appointed C. Michael Gibson as the Chairman of SAB. Dr. Gibson brings almost 3 decades of expertise in cardiology as a scientist. The company welcomes Mr. Gibson on account of the Board executives team.

    He is a valuable asset for BEAT because his scientific expertise will be invaluable in advancing the product development, which will include an ER solution for more accurate MI diagnosis and a comprehensive telehealth system for remote MI monitoring.

    Appointment of Chief Operating Officer by BEAT – Worth it?

    BEAT announced on 22nd December 2021 that Alan Baumel has been appointed as the Chief Operating Officer. Mr. Baumel has a background of product development, production, quality assurance, and regulatory affairs specialist with over 35 years of experience.

    BEAT is happy to be welcome Alan to the Company on behalf of the board of directors. Furthermore, Alan’s vast experience and industry understanding will be critical in hastening industrialization and FDA product development. Alan’s extensive experience, particularly with cardiac devices, makes him a perfect fit for the heart attack detection and monitoring system. Last but not the least, Alan will not only strengthen the fundamental management team but will also help the team to commercialize and scale the technology.